Technologies

Aliophen-XP is a highly concentrated polyphenolic composition derived from Aliophen®, a patented formulation based on malt and hops (Patent No. 102017000096298). Developed to enhance the original formulation, Aliophen-XP is produced through a specialized process that removes components potentially interfering with the biological activity of the bioactive compounds naturally extracted from malt and hops.

Method for extracting, with high yield, phycobiliproteins from cyanobacterial and/or algal biomass, obtaining aqueous extracts characterized by high concentration of pigments (4-5 mg/mL)  and a purity, at least equal to food/cosmetic grade (P≥2).

Anthocyanins are antioxidant polyphenolic pigments produced by plants that are widely used in the food, cosmetic and pharmaceutical industries. The technology allows to obtain in a short time potato cell lines in which the production of highly acetylated and highly complex anthocyanins is increased in addition to other antioxidant polyphenolic compounds. The obtained cellular lines have a high production efficiency, comparable to the extraction of berries, but with the advantage of having an on-demand production which is not limited to seasonality.

The environment as well as the food production provide a number of both natural and synthetic compounds whose effects on human being as an organism have not yet been determined nor investigated.

The proposed technology is about the development of an innovative sunscreen obtained from cod fish bones, according to the principles of the circular economy. The sunscreen is a reddish powder, which is constituted of hydroxyapatite (a calcium phosphate main component of human bones) modified with iron. It is prepared with a simple and easily scalable process (treatment of the bones in Fe solution and successively at T = 700 oC) and could be adapted for bones of other fishes. 

We present a technology for the multiscale isolation (analytical-laboratory-production) of Extracellular Vesicles (VE), which overcomes the limitations of the currently available methods. As opposed to traditional "affinity-based" systems that exploit antibodies, our technology represents a radical paradigm shift in the development of affinity probes for vesicles, i.e.